As clearly illustrated in Figure 8C, there was a direct correlation between the treatment outcome and extent of tumor infiltration of CD45+ immune cells among αPD-L1 and combination-treated groups compared to controls, effectively demonstrating that the beneficial responses were observed in tumors harboring a high fraction of CD45+ cells. This evidence concerns the gene PTPRC and neoplasm.